Ibandronic Acid Synthon

Ibandronic Acid, the active ingredient in Ibandronic Acid Synthon, is a bisphosphonate presented as an oral formulation for oral use. It is indicated for the treatment of osteoporosis in postmenopausal women and glucocorticoid‑induced cases, as well as for Paget’s disease of bone.

GNH USA supplies Ibandronic Acid Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Ibandronic Acid is a bisphosphonate used to manage bone‑resorptive disorders.

- Osteoporosis (postmenopausal): reduces risk of vertebral and non‑vertebral fractures by increasing bone mineral density. - Osteoporosis (glucocorticoid‑induced): improves bone strength and helps prevent fractures in patients receiving long‑term glucocorticoid therapy. - Paget’s disease of bone: normalizes abnormal bone remodeling and alleviates associated pain.

Ibandronic Acid may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of queasiness that may lead to vomiting. - Dyspepsia: indigestion with bloating or heartburn. - Musculoskeletal pain: aches in muscles or joints.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the oral cavity that fails to heal. - Atypical femur fracture: unusual break in the thigh bone occurring with minimal trauma. - Severe esophagitis: inflammation or ulceration of the esophagus that can cause pain and difficulty swallowing.

Before prescribing Ibandronic Acid, clinicians should evaluate patient‑specific risk factors and follow safety measures.

- Renal function assessment: evaluate kidney function before initiating therapy and monitor periodically. - Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk. - Esophageal health: avoid administration in patients with active esophageal disorders. - Concomitant bisphosphonate use: do not combine with other agents of the same class. - Hydration: advise patients to maintain adequate fluid intake. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ibandronic Acid can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Other bisphosphonates: concurrent use may increase risk of severe bone toxicity. - Oral calcium or antacids containing aluminum/magnesium: taken within 2 hours can impair absorption. - NSAIDs: combined use may heighten gastrointestinal irritation.

Moderate Interactions (Monitor Closely): - Corticosteroids: may exacerbate bone loss, requiring closer monitoring. - Proton pump inhibitors: can affect gastric pH and drug absorption. - Warfarin: potential for altered anticoagulant effect, necessitating INR checks.